AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03007823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study NCT03953027 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02459067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImmuniCell®
Description: Autologous γδ T Lymphocytes
Study NCT05115162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
Study NCT06777069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leucocyte and platelet rich fibrin membrane application
Description: Leukocyte and platelet rich membrane, obtained by centrifuging 10 ml of venous blood collected from the patient's antecubital vein, was sutured to the donor sites.
Study NCT00548769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study NCT00548769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study NCT00548769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study NCT00548769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study NCT01946711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation
Study NCT01946711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Nasal spray
Study NCT01873794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright white light
Study NCT01873794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim red light
Study NCT00209313 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acyclovir
Description: Acyclovir 800 mg twice daily or placebo
Study NCT00598689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% hypromellose
Description: 0.3% hypromellose four times a day for 5 days prior to LASIK surgery
Study NCT02239718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-unit cantilevered resin bonded bridge
Description: Use one tooth as abutment tooth to replace one adjacent missing tooth
Study NCT02239718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-unit fixed movable resin bonded bridge
Description: Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
Study NCT02629510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil
Study NCT02812810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Study NCT02812810 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Study NCT03215446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anaesthesia with propofol
Study NCT03215446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance of anaesthesia with sevoflurane
Study NCT02374827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postpartum tubal ligation
Description: Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
Study NCT02374827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Salpingectomy
Description: Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
Study NCT03681028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Individualized therapy
Description: 1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose.
Study NCT03911492 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SCPP Management => 65 mmHg
Description: A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
Study NCT00740545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparine 40 mg daily
Description: Women inject ourselves every days with 40 mg of enoxaparine
Study NCT00740545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Women inject ourselves every days with placebo
Study NCT00605241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK598809
Description: Drug
Study NCT00820768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-010
Description: 17-AAG and ABI-007
Study NCT03293823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSOP training
Description: a computerized cognitive training of attention and processing speed
Study NCT03293823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MLA control
Description: a computerized cognitive intervention of multiple mental leisure activities
Study NCT03414138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
Study NCT03414138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Listening Control
Description: Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
Study NCT01777919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT01777919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Study NCT01777919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Study NCT00206648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: Betaseron 250 µg SC every other day
Study NCT03244397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy + educational strategy
Description: See arm/group descriptions
Study NCT03244397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational strategy
Description: See arm/group descriptions
Study NCT03256175 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
Study NCT03256175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
Study NCT01090128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin Bound Paclitaxel
Description: IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
Study NCT01090128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks
Study NCT01090128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m2 given every 3 weeks
Study NCT01407679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Description: 1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1: 26-35(27L) Peptide
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study NCT00206648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaferon/Betaseron
Description: Avonex 30 µg IM once per week
Study NCT02094703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study NCT02094703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT02094703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Study NCT02094703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Solifenacin succinate)
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:154-162 Peptide
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study NCT02180646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein breakfast
Description: a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
Study NCT02180646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carb breakfast
Description: a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
Study NCT00053833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT via rectal enema
Description: 50 grams of FMT via rectal enema
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: FMT capsules given twice daily for 2 consecutive days
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered orally
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered IV
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via rectal enema
Description: Placebo via rectal enema
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via rectal enema
Description: Placebo via rectal enema
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules given twice daily for 2 consecutive days
Study NCT00923195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Administered orally
Study NCT00923195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
Study NCT00923195 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-gp 100:154 TCR PBL
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14
Study NCT00923195 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-MART-1 F5 TCR PBL
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14
Study NCT03412019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Selections of Mozart piano sonatas
Study NCT06201182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules given twice daily for 2 consecutive days
Study NCT01673165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skimmed mother's milk
Description: Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
Study NCT01673165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized Formula
Description: Infants will receive our standard of care - specialized formula
Study NCT02172716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed.
Study NCT00525031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
Study NCT00525031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha-2b (PGI)
Description: 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
Study NCT01174641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: trans-cranial magnetic stimulation
Description: 1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
Study NCT01174641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-cranial magnetic stimulation
Description: trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
Study NCT03227822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short spot stenting
Study NCT03227822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long lesion stenting
Study NCT00975130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC golimumab
Description: Subcutaneous golimumab at a dose of 50 mg administered once monthly.
Study NCT00975130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV golimumab
Description: Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
Study NCT02729194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT02729194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Description: Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
Study NCT01656954 — intervention group
Intervention type: PROCEDURE
Intervention: Passive Leg Raise (PLR)
Description: From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
Study NCT04324398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: cold application
Study NCT04006977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a multistrain probiotic product (DSF)
Description: In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
Study NCT04006977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Arm 1, participants will receive standard medical therapy plus the placebo.
Study NCT03975283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: 266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
Study NCT03975283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: 0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
Study NCT00746954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Cabonic Anhydrase inhibitor
Study NCT00746954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buspirone
Description: Agonist of a 5-HT1a receptor with some D2 agonist properties.